III. Contraindications

IV. Dosing

  1. Trade name formulations (Tricor, Antara, Fenoglide, Lipofen, Triglide) have a confusing mix of dosing options
  2. Generic Tablets 54 to 160 mg orally daily (maximum 160 mg/day)
  3. Generic Capsules 67 to 200 mg orally daily (maximum 200 mg/day)
  4. Reduce dose in Renal Insufficiency

V. Mechanism

VI. Efficacy

VII. Adverse Effects

  1. See Fibric Acid Derivative
  2. Less likely than other Fibrates to cause Rhabdomyolysis with Statin

VIII. Safety

  1. Unknown safety in pregnancy
  2. Avoid in Lactation

IX. Drug Interactions

XI. References

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

fenofibrate (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
FENOFIBRATE 120 MG TABLET Generic $12.34 each
FENOFIBRATE 130 MG CAPSULE Generic $0.66 each
FENOFIBRATE 134 MG CAPSULE Generic $0.13 each
FENOFIBRATE 145 MG TABLET Generic $0.16 each
FENOFIBRATE 150 MG CAPSULE Generic $5.59 each
FENOFIBRATE 160 MG TABLET Generic $0.18 each
FENOFIBRATE 200 MG CAPSULE Generic $0.19 each
FENOFIBRATE 40 MG TABLET Generic $6.58 each
FENOFIBRATE 43 MG CAPSULE Generic $0.33 each
FENOFIBRATE 48 MG TABLET Generic $0.10 each
FENOFIBRATE 54 MG TABLET Generic $0.09 each
FENOFIBRATE 67 MG CAPSULE Generic $0.11 each

Ontology: Fenofibrate (C0033228)

Definition (NCI) A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol.
Definition (NCI_NCI-GLOSS) A drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent.
Definition (MSH) An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
Definition (PDQ) A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates perioxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459750&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=459750&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29047" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D011345
SnomedCT 108603001, 386879008
LNC LP171398-3
English Phenofibrate, Procetofene, Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester, fenofibrate, fenofibrate (medication), FENOFIBRATE, Procetofen, fenofibrates, phenofibrate, Fenofibrate [Chemical/Ingredient], Fenofibrate, Fenofibrate (product), Fenofibrate (substance)
Swedish Procetofen
Finnish Proketofeeni
Russian LIPANTIL, PROTSETOFEN, ПРОЦЕТОФЕН, FENOFIBRAT, ФЕНОФИБРАТ, ЛИПАНТИЛ
Japanese フェノフィブラート, フェノヒブレート, リパンチル, フェノフィブレート, プロセトフェン
French Fénofibrate, Procétofène
Czech fenofibrát, procetofen
Spanish Fenofibrato, Procetofeno, fenofibrato (producto), fenofibrato (sustancia), fenofibrato
Portuguese Fenofibrato, Procetofeno
Polish Lipantyl, Fenofibrat, Procetofen
Italian Fenofibrato
German Fenofibrat, Procetofen